Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia.
OBJECTIVE
To propose a protocol for minimizing medical complications associated with the use of cyproterone, medroxyprogesterone, and depot leuprolide to treat paraphilia.


METHODS
Review of the relevant literature.


RESULTS
Certain patient populations should not be treated with these medications, and medical complications associated with each can be detected early and avoided.


CONCLUSIONS
For each drug, a series of screening tests prior to use and scheduled testing during use can minimize potential medical complications.
Reilly
D R
DR
University of Ottawa, Ontario.
Delva
N J
NJ
Hudson
R W
RW
D000284:Administration, Oral; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007273:Injections, Intramuscular; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000009:adverse effects; D010262:Paraphilic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology
D000726:Androgen Antagonists; D017373:Cyproterone Acetate; D016729:Leuprolide; D008525:Medroxyprogesterone